Literature DB >> 30212710

Down-regulation of microRNA-21 reduces inflammation and podocyte apoptosis in diabetic nephropathy by relieving the repression of TIMP3 expression.

Xiaoping Chen1, Lei Zhao2, Yanwei Xing3, Bo Lin4.   

Abstract

BACKGROUND: Several miRNAs including miR-21 have emerged as important regulators in the development of diabetic nephropathy (DN). However, the molecular mechanism of miR-21 underlying DN pathogenesis remains to be further discussed.
METHODS: Streptozotocin (STZ)-induced DN rats and high glucose (HG)-induced podocytes were used as the in vivo and in vitro models of DN. miR-21 level was detected by qRT-PCR assay. Inflammatory cytokine levels were assessed by ELISA. Kidney injury of rats was evaluated by blood glucose, serum creatinine and blood urine nitrogen concentrations and periodic acid schiff (PAS) staining. Apoptosis in kidney tissues and podocytes was determined by TUNEL and flow cytometry analyses, respectively. Western blot analysis was applied to measure the protein levels of tissue inhibitors of metalloproteinase 3 (TIMP3), Bax and Bcl-2. The relationship between TIMP3 and miR-21 was confirmed by luciferase reporter assay.
RESULTS: miR-21 expression was upregulated in serum and kidney tissues of DN patients, kidney tissues of STZ-induced DN rats, and HG-treated podocytes. miR-21 depletion inhibited pro-inflammatory factor (IL-1β, TNF-α) secretions and alleviated kidney damages in STZ-induced DN rats. Moreover, TIMP3 was a target of miR-21 in HG-treated podocytes. Additionally, TIMP3 overexpression abated HG-induced inflammatory responses and podocyte apoptosis. Furthermore, the inhibitory effects of TIMP3 on inflammatory responses and podocyte apoptosis were alleviated by increased miR-21.
CONCLUSION: The down-regulation of miR-21 inhibited the progression of DN by targeting TIMP3 in STZ-induced DN rats and HG-treated podocytes, elucidating a novel regulatory mechanism of miR-21 in DN progression and offering a potential target for DN therapy.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Diabetic nephropathy; High glucose; Streptozotocin; TIMP3; miR-21

Mesh:

Substances:

Year:  2018        PMID: 30212710     DOI: 10.1016/j.biopha.2018.09.007

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  22 in total

Review 1.  MicroRNAs in kidney injury and disease.

Authors:  Nassim Mahtal; Olivia Lenoir; Claire Tinel; Dany Anglicheau; Pierre-Louis Tharaux
Journal:  Nat Rev Nephrol       Date:  2022-08-16       Impact factor: 42.439

Review 2.  Epigenetics in kidney diseases.

Authors:  Hao Ding; Lu Zhang; Qian Yang; Xiaoqin Zhang; Xiaogang Li
Journal:  Adv Clin Chem       Date:  2020-10-21       Impact factor: 6.303

Review 3.  MicroRNA-21: A Critical Pathogenic Factor of Diabetic Nephropathy.

Authors:  Shuijiao Liu; Weizhou Wu; Jian Liao; Fuqin Tang; Ge Gao; Jing Peng; Xiujing Fu; Yuqin Zhan; Zhihui Chen; Weifang Xu; Shankun Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-05       Impact factor: 6.055

Review 4.  Biology of Tissue Inhibitor of Metalloproteinase 3 (TIMP3), and Its Therapeutic Implications in Cardiovascular Pathology.

Authors:  Dong Fan; Zamaneh Kassiri
Journal:  Front Physiol       Date:  2020-06-16       Impact factor: 4.566

5.  MiR-21-3p Plays a Crucial Role in Metabolism Alteration of Renal Tubular Epithelial Cells during Sepsis Associated Acute Kidney Injury via AKT/CDK2-FOXO1 Pathway.

Authors:  Zhuoyong Lin; Zhongwei Liu; Xi Wang; Chuan Qiu; Shixiang Zheng
Journal:  Biomed Res Int       Date:  2019-05-16       Impact factor: 3.411

6.  The protective effect and mechanism of catalpol on high glucose-induced podocyte injury.

Authors:  Yan Chen; Qingpu Liu; Zengfu Shan; Yingying Zhao; Meng Li; Baiyan Wang; Xiaoke Zheng; Weisheng Feng
Journal:  BMC Complement Altern Med       Date:  2019-09-05       Impact factor: 3.659

7.  MiR-770-5p facilitates podocyte apoptosis and inflammation in diabetic nephropathy by targeting TIMP3.

Authors:  Li Wang; Hua Li
Journal:  Biosci Rep       Date:  2020-04-30       Impact factor: 3.840

Review 8.  Noncoding RNAs in Diabetic Nephropathy: Pathogenesis, Biomarkers, and Therapy.

Authors:  Jiarong Lv; Yu Wu; Yifeng Mai; Shizhong Bu
Journal:  J Diabetes Res       Date:  2020-06-19       Impact factor: 4.011

Review 9.  MicroRNAs in Podocyte Injury in Diabetic Nephropathy.

Authors:  Hiroki Ishii; Shohei Kaneko; Katsunori Yanai; Akinori Aomatsu; Keiji Hirai; Susumu Ookawara; Kenichi Ishibashi; Yoshiyuki Morishita
Journal:  Front Genet       Date:  2020-08-25       Impact factor: 4.599

Review 10.  Interactions Among Non-Coding RNAs in Diabetic Nephropathy.

Authors:  Tamil Selvi Loganathan; Siti Aishah Sulaiman; Nor Azian Abdul Murad; Shamsul Azhar Shah; Abdul Halim Abdul Gafor; Rahman Jamal; Noraidatulakma Abdullah
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.